Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study.

Pasi, John; Hermans, Cédric; Hakimi, Zalmai; Nazir, Jameel; Aballéa, Samuel; Ezzalfani, Monia; Fatoye, Francis

Pasi, John; Hermans, Cédric; Hakimi, Zalmai; Nazir, Jameel; Aballéa, Samuel; Ezzalfani, Monia; Fatoye, Francis.

Afiliação

Pasi J; Barts and The London School of Medicine and Dentistry, Haematology Day Unit and Haemophilia Centre, 2nd Floor, Central Tower, The Royal London Hospital, Whitechapel, London E1 1BB, UK.
Hermans C; Division of Hematology, Hemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain, Brussels, Belgium.
Hakimi Z; Swedish Orphan Biovitrum AB, Stockholm, Sweden.
Nazir J; Swedish Orphan Biovitrum AB, Stockholm, Sweden.
Aballéa S; Creativ-Ceutical, Rotterdam, The Netherlands.
Ezzalfani M; Creativ-Ceutical, Paris, France.
Fatoye F; Department of Health Professions, Faculty of Health and Education, Manchester Metropolitan University, Manchester, UK.

Ther Adv Hematol ; 13: 20406207221079482, 2022.

Article em En | MEDLINE | ID: mdl-35237394